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Abstract
Extranodal marginal zone lymphomas (EMZL) are the most common lymphomas in the ocular adnexa. The etiology and
potential role for antigenic stimulation in these lymphomas are still controversial. We have examined IGHV gene usage and
mutations in 67 Chlamydophila psittaci-negative ocular adnexal EMZL. Clonal IGHV gene sequences were identified in 43
tumors originating from the orbit (19), conjunctivae (18) and lacrimal gland (6). Forty four potentially functional clonal IGHV
gene sequences were detected with overrepresentation of the IGHV4 family and IGHV4-34 gene. All but 3 sequences were
mutated with the average percent homology to the germ line of 93.566.1. Multinomial model and Focused binomial test
demonstrated evidence for positive and/or negative antigen selection in 59% of the potentially functional IGHV genes.
Intraclonal variation was detected in 8 of 11 tumor specimens. Overall our findings demonstrate that C. psittaci-negative
ocular adnexal EMZL exhibit biased usage of IGHV families and genes with evidence for intraclonal heterogeneity and
antigen selection in multiple tumors, implicating B-cell receptor-mediated antigen stimulation in the pathogenesis of these
lymphomas.
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Introduction
Extranodal marginal zone lymphomas (EMZLs) are a distinct
subtype of Non-Hodgkin’s lymphoma (NHL) typically arising in
extranodal sites devoid of significant lymphoid tissue, such as the
gastrointestinal tract, thyroid and salivary glands, lungs, skin and
the ocular adnexa (lacrimal gland, orbit, conjunctiva and eyelid)
[1,2]. EMZLs are frequently characterized by an indolent clinical
course and often remain localized at their sites of origin for many
years. In some locations, these lymphomas are preceded by the
acquisition of reactive localized inflammatory infiltrates caused by
long-standing chronic infection (e. g. Helicobacter pylori in the
stomach) or autoimmune diseases (e.g. Hashimoto’s thyroiditis in
the thyroid and Sjogren’s syndrome in the salivary glands)
suggesting pathogenetic dependence on antigen stimulation and/
or help provided by the local immune reactions [2,3,4,5,6].
Remission of early gastric EMZLs following Helicobacter pylori-
eradicating antibiotics supports this mechanism of lymphoma
pathogenesis [3,4].
In contrast, the etiology and pathogenesis of ocular adnexal
extranodal marginal zone lymphomas (OAEMZLs) are still
controversial [7]. In a prospective case-controlled study from
Italy, a significant association was demonstrated between exposure
to household animals, rural residence, and history of chronic
conjunctivitis in patients with OAEMZLs [8]. Furthermore, the
Italian group and investigators from several other geographic
regions demonstrated Chlamydophila psittaci (C. psittaci) DNA and
bacteria present in OAEMZLs [7,8,9,10,11,12], suggesting that
this pathogen may be implicated in the development of these
lymphomas analogously to Helicobacter pylori in gastric EMZLs.
However, similar studies performed by us and other investigators
on US and non-US-based patients have failed to corroborate
the finding of C. psittaci in OAEMZLs, potentially suggesting
geographic differences [7,13,14,15,16]. Furthermore, DNA from
other bacteria was also not detected, which supports a non-
bacterial etiology in Florida US patients [17].
The majority of B-cell lymphomas express a unique clonal
surface B-cell receptor containing an immunoglobulin (Ig) heavy
chain variable region (IGHV) that may have important implica-
tions for tumor diagnosis and pathogenesis. The following
approaches can be useful to trace the developmental stage at
which neoplastic B cell transformation occurs and provide support
for B-cell receptor-mediated direct antigen stimulation of lympho-
ma cells without prior antigen identification: (1) examining
possible bias in IGHV-gene usage; (2) analyzing the distribution
of silent (S) and replacement (R) mutations in framework regions
(FR) and complementary determining regions (CDR); (3) evalu-
ating the CDR3 sequences; and (4) investigating the presence of
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mutations. Several groups have analyzed the IGHV gene in small
cohorts of patients (range 8–26) with OAEMZLs [18,19,20,21,22];
however, these studies have not yielded consistent results. To
further elucidate the potential bias in IGHV gene usage and more
robustly examine evidence for antigen selection, we analyzed
IGHV gene sequences derived from fresh tumor samples in a large
cohort of C. psittaci-negative, untreated OAEMZLs.
Results
Usage of IGHV genes in OAEMZLs
DNA extracted from fresh OAEMZL tumors from 67 patients
(median age 63, range 24–92; 39 females and 28 males) was used
for PCR amplification of the IGHV gene. The tumors originated in
the orbit (29), conjunctiva (26), lacrimal gland (11) and eyelid (1).
All specimens were negative for C. psittaci. Tumors from 34 of these
67 patients were used in our previous studies evaluating the
presence of C. psittaci and other bacteria in OAEMZL [13,17].
Agarose gel examination detected a PCR amplicon of the
appropriate size for amplified IGHV in all 67 tumors. However,
in 24 (36%) tumors, a clonal IGHV-IGHJ PCR sequence could not
be identified, despite successful actin amplification, which served
as a control for DNA integrity.
A total of 45 clonal IGHV sequences were detected in 43
patients, 23 females and 20 males, with a median age of 63 (range
39–92), representing 64% of the analyzed cohort. In two tumors
two clonal sequences were detected in each tumor. Tumors with
detected clonal sequences originated from the orbit (19),
conjunctiva (18) and lacrimal gland (6). No differences in clinical
features and tumor localization between patients with or without
clonal IGHV sequences were detected. In 14 (32.6%) cases the
PCR product could be sequenced directly, whereas in 29 (67.4%)
cases, PCR amplicons had to be subcloned to identify the IGHV-
IGHJ gene sequence.
A total of 44 identified clonal IGHV sequences were potentially
functional (Table 1), while one sequence encoded by IGHV2-26*1
harbored an out-of-frame junction with a stop codon. This
nonfunctional sequence was identified in a tumor that did not
harbor another potentially functional clonal IGHV sequence. The
44 potentially functional IGHV were derived from 4 of the 7
human IGHV gene families with the following distribution: IGHV1,
11.4%; IGHV2, 2.2%; IGHV3, 40.9% and IGHV4, 45.5%. In
comparison to the relative complexity of functional germline IGHV
genes within each family and to the use of IGHV families in
peripheral and lymph node lymphocytes in healthy donors
[23,24,25,26] (Table 2), the IGHV gene family usage by the
OAEMZLs was biased with overrepresentation of the IGHV4 gene
family (p=0.001). The IGHJ segments in the potentially functional
amplicons were derived from 5 of the 6 families with the following
distribution: IGHJ2, 11.4%; IGHJ3, 4.5%; IGHJ4, 43.2%; IGHJ5,
22.7% and IGHJ6, 18.2%. Their usage was also significantly
different from the reported repertoire in peripheral blood
lymphocytes (p,0.001), with an over-representation of IGHJ2
and IGHJ5 [25].
The most frequently encountered genes were IGHV4-34
(n=8), IGHV3-30 (n=6) and IGHV3-23 (n=5) (Table 1) which
are known to frequently encode autoantibodies [25,27,28].
IGHV4-34 and IGHV3-30 were used at higher frequency than
expected in normal individuals [25]. Specifically, the most
commonly used gene, IGHV4-34, represented 18.2% of all the
potentially functional IGHV genes identified in this study in
contrast to its 3–9% prevalence in adult peripheral B lymphocytes
[25,29]. Similarly, IGHV4-34 was also detected once (3.2%)
among 31 IGHV genes sequenced from normal adult marginal
zone lymphocytes [30].
Mutation Pattern and CDR3 Analyses of Potentially
Functional IGHV genes
A total of 41 potentially functional clonal IGHV gene sequences
harbored mutations, with 32 exhibiting more than a 2% difference
from the most similar germline gene sequences and 9 sequences
harboring a 2% or less difference. A total of 3 clonal IGHV gene
sequences exhibited a germline sequence without mutations. The
average percent homology to the germ line sequence in the 41
potentially functional mutated sequences was 93.5% (range 71.5–
99.6). Eight of the 44 (18.2%) potentially functional IGHV gene
isolates differed by more than 10% from the most similar germline
counterpart. In the two tumors which each had two potentially
functional IGHV gene isolates there was a 5 and 14% difference in
the mutation load between the two sequences from the same
tumor, respectively. Two of the three IGHV3-30 sequences
harbored a 2% or less difference from the most similar germline
genes, while all the IGHV3-23 and most IGHV4-34 sequences had
more than a 2% difference from the most similar germline genes.
OAEMZLs did not exhibit excessive accumulation of acceptor
sequence motifs for N-glycan addition.
We next examined if the observed mutations in the OAEMZL
IGHV regions tend to occur in the RGYW/WRCY sequences
usually targeted by AID [31] and WA/TW sequences usually
arising as a polymerase error during repair of the AID-generated
lesions [32]. Overall, 51.7% of mutations observed in the
OAEMZL cases occurred in AID target/error prone repair
regions (30% and 21.7%, respectively), while only 23.4% and
17.7% of the germline genes consisted of areas subjected to AID
action and error-prone repair, respectively. Overall, 7.9% of
polymerase error-prone repair targets and 8.3% of AID targets
were mutated as compared to 5.3% for the rest of the germline
sequences, indicating a bias in mutation patterns toward
mutational hotspots, as previously reported [31,32].
To analyze for potential antigen selection pressure on the IGHV
genes, we applied two algorithms: the Multinomial Model and
Focused binomial test (Table 1). Both algorithms were used since
presently there is no biologically confirmed method that precisely
estimates antigen selection and each of these two most commonly
used methods is associated with potential limitations: interaction
between positive and negative selections in the multinomial model
and underestimation of positive selection in the CDR regions by
the Focused binomial test [33]. The Multinomial algorithm for
antigen selection revealed evidence for positive selection manifest-
ed by an excess of replacement (R) mutations in the CDR
exceeding that expected to occur by chance in 15 sequences.
Negative selection manifested by a scarcity of R mutations in the
FR was detected in 17 sequences. In 7 OAEMZL tumors a
concomitant scarcity of R mutations in FRs and excess of R
mutations in CDRs were observed. Selection analysis using the
Focused binomial test demonstrated evidence of selection in the
FR in 13 sequences and in the CDR in 4 sequences. The markedly
smaller number of cases with selection in the CDR by the Focused
binomial test as compared to the Multinomial model could be
predicted, since the former test is known to underestimate positive
selection in the CDR [33]. Selection was detected in all 5 IGHV3-
23 and 6 of the 8 functional IGHV4-34 sequences by either of the
two models.
We performed a search for similar R mutations within the
CDRs of isolates belonging to the same IGHV genes (Table 3).
Recurrent amino acid changes were observed in the CDR1 and
CDR2 of the IGHV4-34, IGHV3-30 and IGHV3-23 sequences.
IGHV Use in Ocular Adnexa MALT Lymphoma
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Patient
Number Location V Gene J gene
V Gene
Homology
FR
R
FR
S
CDR
R
CDR
S
P-Value FR
Lossos
P-Value
CDR Lossos
P-Value
FR CLIP
P-Value
CDR CLIP
2491 Conjuctiva IGHV3-74*01 IGHJ4*02 97.5 3 0 3 1 0.16861 0.03427 0.389 0.0802
3050 Conjuctiva IGHV1-3*01 IGHJ5*02 99.3 2 0 0 0 0.79635 0.61902 0.189 NA
3145 Orbit IGHV3-11*01 IGHJ4*02 95.4 6 4 3 0 0 0.17078 20.251 20.5
3198 Orbit IGHV4-34*02 IGHJ4*01 77.5 29 13 21 1 0.00233 0.00001 20.00514 0.182
3687 Conjuctiva IGHV3-11*01 IGHJ4*02 94.7 8 3 4 0 0 0.08868 20.251 0.342
4277 Orbit IGHV4-34*01 IGHJ4*02 93.6 8 3 5 2 0.06021 0.04022 20.292 0.17
4438 Lacrimal IGHV4-34*01 IGHJ6*02 100 0 0 0 0 NA NA NA NA
4672 Orbit IGHV4-59*01 IGHJ6*03 99.3 0 0 2 0 0.07201 0.00773 NA 0.0389
4694 Lacrimal IGHV3-23*01 IGHJ5*02 90.9 10 8 5 3 0.00838 0.17802 20.00616 20.0477
4726 Orbit IGHV4-34*01 IGHJ6*02 89.8 9 11 7 2 0.00031 0.04055 21.50E-5 20.303
4784 Lacrimal IGHV4-4*07 IGHJ5*02 100 0 0 0 0 NA NA NA NA
4942 Orbit IGHV2-5*10 IGHJ3*01 95.1 10 2 1 1 0.76707 0.73414 20.457 20.192
4968 Conjuctiva IGHV3-30*03 IGHJ6*02 94.7 8 2 4 1 0.2487 0.0845 0.408 0.195
5334 Conjuctiva IGHV4-59*01 IGHJ5*02 96.4 4 1 4 1 0.08753 0.01566 20.259 0.293
5547 Conjuctiva IGHV1-69*01 IGHJ4*02 94 8 6 2 1 0.09378 0.50383 20.0264 20.12
5859 Orbit IGHV3-66*02 IGHJ4*02 96.8 4 2 3 0 0.14258 0.05382 20.442 0.179
5897 Orbit IGHV4-39*01 IGHJ5*02 86.9 20 9 8 1 0.15982 0.11506 20.106 20.316
5984 Lacrimal IGHV4-34*01 IGHJ4*02 90.1 14 7 7 0 0.0852 0.03391 0.389 0.0845
6092 Orbit IGHV3-23*01 IGHJ4*02 93.4 5 5 8 1 0.00102 0.00095 20.0116 0.386
6574 Conjuctiva IGHV3-30*03 IGHJ4*03 97.2 8 0 0 0 0.98906 0.84086 0.367 20.118
6901 Conjuctiva IGHV1-24*01 IGHJ4*02 93.7 8 3 4 3 0.05443 0.12566 20.0491 0.354
7126 Conjuctiva IGHV4-b*02 IGHJ5*02 95.1 6 5 2 1 0 0.42527 20.0979 20.193
7513 Conjuctiva IGHV3-66*01 IGHJ4*02 91.9 12 4 6 1 0.14813 0.03733 20.21 0.459
7806 Lacrimal IGHV1-46*01 IGHJ4*02 88.1 20 9 2 3 0.28245 0.88855 20.0342 20.012
11274 Orbit IGHV3-23*01 IGHJ4*02 84 18 12 15 1 0.00093 0.00031 20.00472 0.459
11498 Lacrimal IGHV3-66*02 IGHJ6*02 99.3 1 1 0 0 0.37303 0.61621 20.276 20.208
11652 Orbit IGHV4-4*02 IGHJ4*02 93 8 8 3 1 0.02871 0.39729 20.0316 20.123
12187 Orbit IGHV3-23*01 IGHJ2*01 95.8 4 4 3 1 0.02615 0.12876 20.0663 20.463
12652 Conjuctiva IGHV3-23*01 IGHJ4*02 95.1 4 5 4 1 0.00699 0.06246 20.0405 0.4695
12823 Conjuctiva IGHV4-34*02 IGHJ5*01 71.5 36 22 20 3 0.00041 0.00123 25.33E 6 20.2081
13051 Orbit IGHV4-59*08 IGHJ5*02 96.1 5 4 1 1 0.1721 0.68027 20.1522 20.0972
13299 Orbit IGHV3-30*16 IGHJ2*01 85.7 20 8 12 1 0.04391 0.00388 20.1231 20.4905
13299 Orbit IGHV4-30-4*01 IGHJ4*03 99.3 2 0 0 0 0.815 0.6283 0.2318 NA
13726 Orbit IGHV3-30-3*01 IGHJ6*02 96.1 1 5 5 0 0.00024 0.00554 20.0063 0.2859
13928 Orbit IGHV1-46*01 IGHJ5*02 91.6 12 5 5 2 0.08998 0.13444 20.2314 0.4528
14394 Orbit IGHV3-30*04 IGHJ6*02 98.2 2 1 1 1 0.17784 0.323 20.2212 20.4097
14425 Conjuctiva IGHV4-30-4*01 IGHJ6*02 99.6 0 1 0 0 0.19586 0.56889 20.1595 20.3041
15137 Conjuctiva IGHV4-34*03 IGHJ2*01 91.5 13 9 0 2 0.2006 0.97983 20.078 20.0039
15523 Conjuctiva IGHV3-30*03 IGHJ4*02 99.6 0 1 0 0 0.18992 0.56667 20.1526 20.2941
15721 Orbit IGHV4-34*01 IGHJ2*01 93.6 9 6 2 1 0.13703 0.53063 20.0645 20.1648
15721 Orbit IGHV4-31*03 IGHJ2*01 99.6 0 0 1 0 0.19465 0.06769 NA 0.1943
16219 Orbit IGHV4-30-4*03 IGHJ5*02 81 28 11 14 2 0.07453 0.01168 20.0927 0.4631
16299 Orbit IGHV4-39*01 IGHJ4*02 100 0 0 0 0 NA NA NA NA
18664 Conjuctiva IGHV3-74*01 IGHJ3*01 90.9 12 8 6 0 0.05611 0.09813 20.0051 20.2759
NA-not applicable.
doi:10.1371/journal.pone.0029114.t001
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serine from the germline region were observed in all three genes,
and were replaced with aspartic acid, glycine, alanine, threonine,
and asparagine, respectively. Additional observed mutations
included changes of isoleucine to valine, asparagine to serine,
and threonine to alanine. The prevalence of recurrent amino acid
changes was higher in the CDR2 region than the CDR1 region,
suggesting that the CDR2 region may markedly contribute to the
paratope of the tumor-derived Ig. Next we compared mutation
patterns present in the CDR2 of the IGHV4-34 from our 8
OAEMZL tumors to 70 sequences originating from normal
peripheral blood, tonsils and marginal zone B cells identified in
GenBank (accession numbers are shown in the Table S1). Except
for recurrent mutations of serine in the second residue that were
observed in both normal B cell and OAEMZL sequences,
recurrent mutations of isoleucine in the first residue to valine,
serine in the forth and sixth residues to aspartic acid and glycine,
respectively, and threonine in the seventh residue to alanine were
not observed in normal B cells (data not shown), suggesting that
the mutations observed in the OALMZL may be tumor antigen
specific. However, future analysis of additional sequences will be
required to confirm this observation.
Analysis of the tumor-derived CDR3 sequences revealed low
similarity and an absence of stereotyped sequences with no
homology to antibacterial and other previously published
antibodies. The average CDR3 isoelectric point was 5.9561.92
(SD). The average CDR3 length was 15.7563.67 (SD) amino
acids, with 19 sequences harboring 10–14 amino acids, 18
sequences harboring 15–19 amino acids and 7 sequences of 20
or more amino acids.
In 22 patients, consisting of 6 cases with 2% or less difference
from the most similar germline gene sequences and 16 cases with
more than 2% difference from the most similar germline gene
sequences, information on clinical presentation and outcome
following localized radiation to the eyes was available with a
median follow up of 31 months (range 2–121). There was no
difference in overall survival and progression free survival between
these two groups of patients (not shown); however, the small
number of cases and clinical events prevents firm conclusions.
Analysis of intraclonal heterogeneity
To assess the presence of intraclonal heterogeneity, extensive
molecular cloning of 11 randomly selected potentially functional
IGHV gene isolates with percent homology to the germ line
sequence ranging from 81.0 to 94.7 was performed (Table 4 and
Figure 1). In three of the tested samples, the extensively mutated
clonal IGHV gene isolates did not show intraclonal heterogeneity.
In 8 samples intraclonal heterogeneity was detected as manifested
by the presence of molecular clones harboring confirmed
mutations not observed in the most abundant clonal IGHV gene
sequence. While single nucleotide mutations accounted for most of
the observed ongoing mutations, deletions were also observed.
Table 2. IGHV Family Usage in Ocular Adnexal Extranodal Marginal Zone Lymphomas.
IGHV Family
OAEMZLs
Present Study (n=44)
(%)
Relative IGHV Family Size
(%) [23]
Adult PBL
( i ns i t uh y b r i d i z a t i o n )( % )[ 2 4 ]
Adult PBL (single
cell PCR) (%) [25]
Adult PBL (PCR)
(%) [26]
IGHV1 11.4 21.5 11 12.7 12
IGHV2 2.2 5.9 3 4.2 1
IGHV3 40.9 43.1 52 56.3 55
IGHV4 45.5 21.6 19 19.7 26
IGHV5 0 3.9 10 5.6 4
IGHV6 0 2.0 5 1.4 2
IGHV7 0 2.0 0 0 0
OAEMZL- Ocular Adnexal Extranodal Marginal Zone Lymphomas.
PBL-peripheral blood lymphocytes.
doi:10.1371/journal.pone.0029114.t002
Table 3. Repeating Mutations in CDR1 and CDR2.
Germline Case Number Site CDR1 CDR2
IGHV4-34
15137 Conjuctiva GGSFSGYY INHSGST
4438 Lacrimal GGSFSGYY INHSGST
15721 Orbit GGSFSAYY INHSGGT
4726 Orbit GGSFTGYY INYAGDP
4277 Orbit GGSLSGYY ISHDGSA
5984 Lacrimal GGSFSGYF VDPSGRA
12823 Conjuctiva GGPLGTNI VSENGET
3198 Orbit GDYFITYA VSQDAGV
Germline GGSFSGYY INHSGST
IGHV3-30
15523 Conjuctiva GFTFSSYG ISYDGSNK
6574 Conjuctiva GFTFSSYG ISYDGSNK
14394 Orbit GFTFSSYA ISYDGSNK
13726 Orbit RFTFSNYA ISYNGNNQ
4968 Conjuctiva GFIFSNYG ISYDGTIK
13299V3 Orbit GFTLSSHG SSFDGTTE
Germline GFTFSSYG ISYDGSNK
IGHV3-23
4694 Lacrimal GFTFSNYA ISGSGSNT
6092 Orbit GFTFSRYV ISASGSNT
12187 Orbit GFTFTTYA IGGSGGST
12652 Conjuctiva GFTFSTYA IGGSGGVT
11274 Orbit TITFNCCA IAASGTGT
Germline GFTFSSYA ISGSGGST
Repeated amino acid substitutions are shown in bold.
doi:10.1371/journal.pone.0029114.t003
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cases with 1 or 2 additional confirmed mutations, similar to our
previous observation in a subset of diffuse large B-cell lymphoma
cases [34]. In two tumors (4694 and 13299), 16 and 56 additional
confirmed mutations were observed, thus leading to extensive
variation between the subclones harboring identical CDR3
regions, similar to intraclonal heterogeneity which is typically
observed in follicular lymphoma [35].
Discussion
OAEMZLs account for up to 55% of all orbital tumors and 8%
of extranodal NHLs [7]. While antigen stimulation, which may be
directly mediated by surface B-cell receptor and/or indirectly
mediated by T cells, is implicated in the pathogenesis of EMZLs in
the thyroid, salivary gland and stomach, the etiology of OAEMZL
is still controversial. C. psittaci may function as the antigenic
stimulus of OAEMZLs in several geographic regions [7,8,11,12];
however, it is not detected in the majority of US patient tumors, in
which the antigen is unknown [13,16,36]. Overall, there is only
scarce published data on the potential role of antigenic stimulation
in this lymphoma.
The present study was undertaken to clarify if there is potential
antigen stimulation in C. psittaci-negative OAEMZLs. To this end,
molecular analysis of the IGHV region was performed in 67
untreated primary OAEMZL patients. The study demonstrates a
biased usage of IGHV families and genes with evidence for
intraclonal heterogeneity and antigen selection in multiple tumors,
implicating B-cell receptor-mediated antigen stimulation in the
pathogenesis of these lymphomas.
In our cohort of C. psittaci-negative OAEMZL patients there was
overrepresentation of the IGVH4 family and specifically the
IGVH4-34 gene segment. Similar biased usage of the IGVH4-34
gene segment was previously suggested by Bahler et al. in a small
cohort of C. psittaci-negative OAEMZL patients from the US [18].
In this study the IGVH4-34 gene segment was detected in 3 of the
10 analyzed cases. In contrast, 4 small studies from Germany and
Japan, analyzing a total of 56 tumors (range 8–26) did not
demonstrate biased usage of the IGVH4 family and IGVH4-34
gene segment [19,20,21,22]. In these 4 studies the IGVH3 family
(64%) was most commonly used. Overrepresentation of IGHV3-
30, seen in our cohort, was not observed in these studies. IGHV3-
23, commonly used in our cohort, was detected in 7 of these 56
cases but was overrepresented only in a study by Adam et al.,
accounting for 3 out of the 8 cases [22]. While all the analyzed US
cases in both studies were negative for C. psittaci, its presence was
not examined in any of the 4 non-US studies [19,20,21,22]. In a
recently accepted, but still not published manuscript that mostly
analyzed patients from European countries, Dagklis et al. also did
not observe biased usage of the IGVH4 family and IGVH4-34 gene
segment [37]. Careful re-evaluation of the data in this manuscript
discloses that IGVH4-34 gene segment was not detected in any of
the 15 C. psittaci-positive OAEMZL tumors, but was observed in 3
of the 21 of the tested C. psittaci-negative OAEMZL. The observed
differences in the use of the IGVH families and genes between the
US and non-US studies most probably stem from different
antigens driving the lymphomagenesis of OAEMZL in distinct
geographic locations, but the small number of analyzed cases,
usage of archived material as a DNA source and differences in
PCR methodologies might also contribute to the observed
discrepancies. Further studies of IGHV in OAEMZL patients with
and without C. psittaci from different geographic regions using
DNA extracted from fresh or frozen tumors will help to clarify the
observed discrepancy.
The gene most commonly used by the C. psittaci-negative
OAEMZL in our patients as well as patients reported by Bahler
et al [18] was IGVH4-34, accounting for 18.2% of the functional
IGVH genes in our cohort. In healthy individuals, IGVH4-34
expressing cells are predominantly identified in naı ¨ve lympho-
cytes and are underrepresented in the germinal center and
memory compartments [27], being used by 3–9% of adult
peripheral B lymphocytes [25,27,29] and in one of 31 IGHV
genes sequenced from normal adult marginal zone lymphocytes
[30]. In lymphomas, the IGVH4-34 gene is overrepresented in
chronic lymphocytic leukemia cases with mutated IGVH genes
(20%) [38] and in primary central nervous system diffuse large B-
cell lymphomas (DLBCL) (60%) [39]. It is not overrepresented in
patients with non- OAEMZLs. In its germline configuration,
without contribution of somatic mutation and to a large extent
independently of the CDR3 region and of associated light chains,
IGVH4-34 frequently encodes intrinsically autoreactive antibodies
that recognize the I/i erythrocyte determinants constituting the
antigenic target of pathogenic autoantibodies in cold agglutinin
disease [40]. The IGVH4-34 gene has also been reported to
Table 4. Analysis of Intraclonal Heterogeneity in Ocular Adnexal Extranodal Marginal Zone Lymphomas.
Case
Number Site of origin
Most Similar
Germline VH Gene
Total No. of Molecular
Clones Evaluated
No. of tumor-derived
Molecular Clones
No. of Confirmed
Additional Mutations
No. of Single Un-
confirmed Mutations
3687 Conjunctiva IGHV3-11*01 11 9 4 4
4694 Lacrimal Gland IGHV3-23*01 14 14 16 8
4726 Orbital IGHV4-34*01 14 14 0 7
5547 Conjunctiva IGHV1-69*01 21 20 1 6
6092 Orbital IGHV3-23*01 13 13 0 6
11274 Orbital IGHV3-23*01 9 9 1 8
11652 Orbital IGHV4-4*02 12 12 2 3
13051 Orbital IGHV4-59*08 11 11 2 2
13299 Orbital IGHV4-30*01 26 22 56* 9
16219 Orbital IGHV4-30*03 11 7 1 8
18664 Conjunctiva IGHV3-74*01 24 24 0 26
*The 56 mutations include 52 single nucleotide changes and 4 deletions ranging from 1–9 base pairs all resulting in potential functional protein.
doi:10.1371/journal.pone.0029114.t004
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antigens, such as DNA, Rh, cardiolipin and lipid-A and is
overrepresented in patients with systemic lupus erythematosus
[28,41]. Two other genes (IGVH3-30 and IGVH3-23) frequently
used by OAEMZLs analyzed in the present study also frequently
encode autoantibodies [25].
The erythrocyte I/i antigens bind to the FR1 region of the
IGVH4-34 [40], a characteristic attributed to B-cell superantigens,
which are supposed to directly activate B cells [42,43,44]. Among
the IGVH4-34 genes cloned from the OAEMZLs analyzed in the
present study, one sequence was not mutated, 3 acquired similar
mutations in the CDR2 and 3 preserved FR sequences, suggesting
a possible role of a yet unknown B cell superantigen that might
drive proliferation and lymphoma development.
The majority (93%) of the potentially functional IGVH genes
isolated from the OAEMZLs analyzed in this study were mutated
as compared to their germline counterparts, suggesting their origin
from a cell that had experienced antigen selection during the
germinal center reaction. This finding is concordant with previous
reports, which also demonstrated somatic mutations in the
majority of EMZLs irrespective of the anatomical site of origin
[45,46]. The observed level of mutations (mean percent homology
to germline of 93.566.1) is also similar to the mutational load
previously reported in both ocular adnexal and other EMZLs
[18,19,20,22,45,46]. However, 15% of the potentially functional
IGHV gene isolates in the current study differed by more than 12%
from the most similar germline counterparts- an uncommon
observation in EMZLs irrespective of the anatomical site of origin.
This extensive mutational load together with the evidence for
positive and/or negative antigen selection (Table 1) in 59% of the
potentially functional IGHV genes by either Multinomial Model
and/or Focused binomial test further suggests that antigens play a
role in the pathogenesis of these lymphomas. The prevalence of
IGHV genes with negative selection may suggest that Ig
preservation may be required for preventing the disruption of
antigen-mediated signaling that could be harmful to lymphoma
Figure 1. Clonal evolution tree in a representative case 11274. HC- hypothetical molecular clone.
doi:10.1371/journal.pone.0029114.g001
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majority of the analyzed OAEMZLs using a very conservative
definition in this study that required the presence of confirmed
ongoing mutations, may further point to the existence of
continuous antigen stimulation in their pathogenesis. Since
EMZLs are in most cases considered to be of post germinal
center origin, the presence of intraclonal heterogeneity in these
tumors may reflect aberrant activation of the somatic mutational
machinery or re-entry into germinal centers for further mutations.
Indeed, colonization of germinal centers is commonly observed in
EMZL biopsies [1] and may reflect re-entry of malignant cells into
germinal centers for additional rounds of antigen selection.
Our methodological approach failed to identify clonal IGHV-
IGHJ PCR product in 36% of tumors that were clinically and
pathologically similar to the tumors in which clonality was
determined. To prevent misidentification of the lymphoma IGHV
genes, we used very strict criteria to define clonality which may
account for some of the observed failures. However, previous
studies reported PCR detection of a monoclonal population in
only 25–70% of EMZL cases [47]. The inability to detect
monoclonal IGHV-IGHJ gene sequences in these cases may result
from the absence of Ig rearrangement, as is rarely observed in
lymphomas [48]. We could not amplify the IGHV-IGHJ gene
sequences of some of these tumors using the BIOMED-2 primers,
while tumor clonality was confirmed by light chain amplification
using the same protocol. Alternatively, somatic mutations in the
region to which the PCR primers are designed to hybridize may
lower amplification efficiency and lead to possible false-negative
results.
Overall our findings demonstrate that C. psittaci-negative
OAEMZLs exhibit biased usage of IGHV families and genes with
evidence for intraclonal heterogeneity and antigen selection in
multiple tumors, implicating B-cell receptor-mediated antigen
stimulation in the pathogenesis of these lymphomas. The nature of
the antigens that potentially play a role in these processes is
currently unknown and requires further studies.
Materials and Methods
Patient material
DNA was extracted from a total of 67 patient fresh biopsy
samples at the time of diagnosis (between 1991 and 2011) of
OAEMZLs using a commercially available kit (QIAamp; Qiagen,
Valencia, CA, USA), as described by the manufacturer. All
pathologic specimens were classified according to the WHO 2008
classification on the basis of the morphologic features observed on
routinely prepared hematoxylin and eosin–stained slides of
formalin-fixed, paraffin-embedded tissues along with immunophe-
notypic and genotypic results [1]. Flow cytometry immunophe-
notyping was performed in most cases and clonality was confirmed
by either Southern blot analysis or polymerase chain reaction
(PCR) for immunoglobulin heavy or light chains in accordance
with the BIOMED-2 recommendations [49]. This study was
approved by the University of Miami Institutional Review Board
(IRB) and written informed consent was obtained according to the
approved protocol.
Detection of C. psittaci DNA
Touchdown enzyme time-release polymerase chain reaction
(PCR) for detection of C. psittaci DNA was performed as previously
reported by us [13]. Blank reactions were always run concomi-
tantly with the DNA from patients’ specimens to monitor for
possible contamination of PCR reagents and to rule out false-
positive results. All reactions were repeated twice.
PCR amplification, cloning and sequencing of IGHV genes
To amplify the IGHV-IGHJ gene sequences, 50–200 ng of DNA
were amplified by GoTaq Green Master Mix (Promega, Madison,
WI) in a final volume of 50 ml containing 10 pmol of a specific 59
primer corresponding to one of the 6 human variable immuno-
globulin heavy chain family leaders (IGHV1 through IGHV6) and
10 pmol of 39 antisense JH consensus primer [48,50]. IGHV1
leader primer also amplifies sequences from the closely related
IGHV7 family. The PCR conditions were: 96uC for 5 minutes,
55uC for 1 minute, 72uC for 3 minutes, 1 cycle; 94uC for
30 seconds, 55uC for 30 seconds, 72uC for 30 seconds, 30 to 35
cycles; and 72uC for 7 minutes. A control with no added template
was used in each PCR reaction to exclude the possibility of
contamination. DNA integrity from patient samples was verified
by amplification of ß-actin using specific PCR primers yielding a
597 base pair (bp) amplicon, as described previously [17]. PCR
products were analyzed by 2% agarose gel electrophoresis and
stained with ethidium bromide. All bands of the appropriate size
were excised from the gels and purified by adsorption to a silica
matrix (QIAquick Gel Extraction Kit, Qiagen). Direct DNA
sequencing of PCR amplicons was performed on a 373 automatic
DNA sequencer (Applied Biosystems, Foster City, CA) using the
ABI Prism Big Dye Terminator Kit (Perkin Elmer, Foster City,
CA), as recommended by the manufacturer. The same primers
used for the PCR were used for sequencing. If a direct DNA
sequencing attempt of the PCR amplicon failed to recover an
unambiguous sequence, the PCR amplicons were cloned using a
TOPO TA cloning kit and OneShot TOP10’ chemically
competent E. coli cells (Invitrogen, Carlsbad, CA) according to
the manufacturer instructions. The colony direct PCR assay was
used to determine whether colonies included the correct PCR
insert. At least 4 colonies from two independent PCRs were
sequenced. Sequences were analyzed with the ImMunoGeneTics
V-Quest (IMGT V-QUEST) software (http://www.imgt.org).
The sequences were defined as clonal if identical CDR3 sequences
were obtained from 2 independent PCR reactions by direct
sequencing. If cloning was performed, at least two sequences with
identical CDR3 from each of the two independent PCRs (a total of
4 identical sequences) were required for definition of clonal
sequence. All the clonal sequences were deposited in GenBank
(JN646046-JN646089).
Analysis of the IGHV sequences
Sequences were compared with known germline genes and
assigned IGHV and IGHJ germline sequence based on the highest
percentage of sequence homology [48]. The length of the CDR3
region and number of somatic mutations were determined.
Mutations at the last nucleotide position of the sequenced
fragment were excluded from the mutational analysis because
they might result from nucleotide deletion at the joining sites [48].
The percent of sequence identity was calculated from the aligned
sequences from the beginning of FR1 to the end of FR3. The total
number of mutations per variable region (FR1-FR3) were added
and normalized to the respective length of each region according
to the IMGT numbering scheme to analyze the relative frequency
of mutations in the different variable regions. The number of
coding (replacement-R) and non-coding (silent-S) mutations were
obtained from IMGT V-QUEST tabulated data. Antigen
selection analysis was performed using the Multinomial Model
[51] and the Z-Test version of the Focused binomial test [52]. For
analysis of recurrent amino acid mutations in the CDR1 and
CDR2 regions, sequences derived from the same germline IGVH
gene in 4 or more specimens were aligned to their corresponding
IMGT assigned germline CDR1 and CDR2 regions by ClustalW
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the CDR3 isoelectric point, the pI/MW application of the
Swiss-Prot/TrEMBL software was used (http://web.expasy.org/
compute_pi/).
Somatic hypermutations tend to occur at hotspots, such as
RGYW/WRCY sequences usually targeted by the mutagenic
enzyme AID [31] and WA/TW sequences usually associated with
mutations in the A:T pairs considered to arise as copying errors
introduced by a DNA polymerase during repair of AID-generated
lesions [32]. To analyze for potential mutation enrichment in these
sequences, we have 1) calculated the percentage of mutations at
these hotspots relative to the total number of mutations observed
in all the analyzed sequences, and 2) examined the prevalence of
mutations in these motifs by normalizing to the relative length of
these hypermutational hotspots across all the clonal germline
sequences detected in the analyzed cohort.
To determine whether homology existed between patients’
CDR3 to the CDR3 of previously reported Ig genes, the amino
acid sequence of patients’ CDR3 region was run through
IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/) and TEIRE-
SIAS algorithm (http://cbcsrv.watson.ibm.com/download.phtml.
html). The previously reported parameters, enabling the connec-
tion of all pairs of sequences that shared at least 50% amino-acid
identity and 70% similarity, were used for this analysis [53].
Analysis of intraclonal heterogeneity
Intraclonal heterogeneity was examined in 11 ocular adnexa
MALT lymphoma specimens by repeated cloning and sequencing
of at least 9 tumor-derived molecular clones from each specimen.
For evaluation of intraclonal heterogeneity, we used previously
proposed definitions [34,48]: confirmed mutation- a mutation
observed more than once in the IGHV gene molecular clones from
the same tumor specimen; unconfirmed mutation- a substitution
mutation observed in only 1 of the IGHV gene molecular clones
from the same tumor specimen. Only the confirmed mutations
were considered as evidence of intraclonal heterogeneity while the
unconfirmed mutations, which may result from Taq polymerase
errors were disregarded.
Statistical Analysis
The usage of the IGHV and IGHJ gene segments in the ocular
adnexa MALT lymphoma specimens was compared to their
utilization in normal peripheral blood lymphocytes by the X
2 test,
with p,0.05 defined as statistically significant. The Multinomial
Model and the Focused binomial test were applied as previously
reported [51,52].
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